New and Noteworthy in May

Upcoming Appearances

May 2nd: Steven Pearson, MD, MSc, ICER’s President, will participate in a panel discussion on prescription drug pricing during the Reining in Prescription Drug Prices conference hosted by the Hutchins Center on Fiscal and Monetary Policy and the Center for Health Policy at Brookings in Washington, DC.

May 3rd: Steve Pearson will participate in the meeting of the Precision Cancer Medicine Consortium in Philadelphia, PA.

May 9th: Sarah Emond, MPP will participate in the Pricing and Reimbursement Panel at the Commercialization Workshop of the American Society of Gene & Cell Therapy, in Washington, D.C.

May 4th Dan Ollendorf, PhD, ICER’s Chief Scientific Officer, will present at United Rheumatology’s Medical Policy Committee Meeting in New York, NY.

May 9th Dan Ollendorf will participate in a panel discussion at Avalon Health Economics’ Symposium on Emerging Trends in U.S. Health Economic Evaluation in Morristown, NJ.

May 23rd: Sarah Emond will participate in Brandeis University’s Princeton Conference on the Implications of the Election for the Health Care System in Princeton, NJ.

Participation in the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2017 Annual International Meeting

ICER leadership and staff will participate in six panel discussions and presentations during the 2017 ISPOR conference held in Boston, MA. In addition, ICER’s work is represented in six poster presentations submitted by ICER staff and collaborators.

May 21st: Steve Pearson will participate in and present work from ICER’s Gene Therapy white paper at the ISPOR HTA Roundtable.

May 22nd : Dan Ollendorf will participate in a workshop titled Good Practices for Synthesizing and Using Evidence in Health Care Decision Making

May 22nd: Dan Ollendorf will participate in an educational symposium titled Is There a Way to Agree on Evidence Requirements Before Evidence is Generated? Panelist Discussion on Challenges Surrounding Heterogeneity of Real World Evidence

May 23rd: Steve Pearson will present during a breakout session titled Making Value Frameworks Fit for Purpose to Guide Decisions: Is there a Need for Empirical Estimates of Opportunity Costs?

May 23rd: Steve Pearson will participate in a panel discussion titled Perspectives on the Relationship between Cost Effectiveness and Affordability.  

May 24th: Bill Dreitlein, PharmD, Director of Pharmaceutical Policy, will moderate a panel discussion titled Developing and Paying for Gene Therapies: Can we Resolve the Conflicts?

Key Dates

May 5th: Draft Evidence Report on Abuse-Deterrent Opioids posted

  • Open to public comment until June 2nd

May 8th: Revised Scoping Document on Chronic Low Back and Neck Pain posted

May 8th: Draft Scoping Document on Tardive Dyskinesia

  • Open to public comment until May 26th

May 10th: Draft Briefing Paper for ICER’s Orphan Drug Assessment and Pricing Summit posted

  • Open to public comment until May 24th

May 12th: Evidence Report on Atopic Dermatitis posted

May 25th: Public meeting of the Midwest CEPAC on Atopic Dermatitis

May 31st: ICER’s Orphan Drug Assessment and Pricing Summit